Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
DUBLIN, Ireland, May 01, 2018 -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories, will announce financial results for the first quarter of 2018 on May 8, 2018 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 8.
About Prothena
Prothena Corporation plc is a global clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of progressive, life-threatening diseases associated with this biology. Prothena is advancing a pipeline of antibody therapeutic candidates for a number of indications and novel targets including Parkinson's disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, Aβ (Amyloid beta), TDP-43 and ALECT2, where its scientific understanding of disease pathology can be leveraged. For more information, please visit the Company's website at www.prothena.com and follow us @ProthenaCorp.
Media & Investor Contact:
Ellen Rose, Head of Communications
650-922-2405, [email protected]
